Author details

Full Name

John-Paul Todd

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37349337	Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.	Nat Commun	2023
37738240	Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus.	PLoS Pathog	2023
37986823	Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.	bioRxiv	2023
38076895	Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates.		2023
37861342	Immune Activation Profiles Elicited by Distinct, Repeated TLR Agonist Infusions in Rhesus Macaques.		2023
36789423	Investigation of the Impact of Clonal Hematopoiesis on Severity and Pathophysiology of COVID-19 in Rhesus Macaques.		2023
37503026	RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.		2023
37483285	Investigation of the impact of clonal hematopoiesis on severity and pathophysiology of COVID-19 in rhesus macaques.		2023
34921774	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.	Cell	2022
35447072	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.	Cell	2022
36157588	Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses.	iScience	2022
34986348	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.	Cell Rep	2022
34417590	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.	Nature Immunology	2021
34075375	Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates.		2021
33907752	Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates.	bioRxiv	2021
33688652	Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.		2021
33826898	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base.	Cell Reports	2021
34315825	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.	Science Translational Medicine	2021
34623326	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.	J Clin Invest	2021
34729558	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway.	bioRxiv	2021
34672695	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.	Science	2021
34551978	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.	Proceedings of the National Academy of Sciences of the United States of America	2021
34426813	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.	bioRxiv	2021
35003140	Development of an <i>In Vivo</i> Probe to Track SARS-CoV-2 Infection in Rhesus Macaques.	Front Immunol	2021
34529476	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.	Science	2021
32722908	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.	N Engl J Med	2020
32755575	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature.	Cell Rep	2020
32522807	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality.	Science Translational Medicine	2020
32690707	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.	Proc Natl Acad Sci U S A	2020
31348886	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.	Cell	2019
29444432	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.	Cell Rep	2018
29867235	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.	Nat Med	2018
30420505	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.	Proc Natl Acad Sci U S A	2018
30517201	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge.	PLoS Pathog	2018
28931639	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.	Science	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
27708058	Rapid development of a DNA vaccine for Zika virus.	Science	2016
27270781	Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.	Nat Med	2016
27158907	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.	Nat Med	2016
26279189	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.	Cell	2015
25787288	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.	Journal of Virology	2015
26218507	Evaluation of candidate vaccine approaches for MERS-CoV.	Nat Commun	2015
26041300	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.	J Virol	2015
26581981	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.	J Virol	2015
26485194	Activation and lysis of human CD4 cells latently infected with HIV-1.	Nature Communications	2015
26446600	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.	Journal of Virology	2015
25142607	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.	J Virol	2014
24352234	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.	Nature	2014
25043006	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression.	Nature	2014
24990883	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.	Sci Transl Med	2014